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Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 platelet adenosine diphosphate (ADP) 
receptor antagonist reduces ischemic events in acute coronary syndrome (ACS) patients 
undergoing percutaneous coronary intervention (PCI) but also increases bleeding [1-3]. 
Residual high on-treatment platelet reactivity (HPR) and low on-treatment platelet reactivity 
(LPR) in response to P2Y12 receptor stimulation, as measured by different platelet function 
testing (PFT) methodologies, are associated with increased risk for ischemic and bleeding 
outcomes, respectively (see [4, 5] and the references contained therein for descriptions of PFT 
assays and definitions of HPR and LPR), suggesting that altering antiplatelet therapy based on 
PFT would reduce adverse events. Small randomized and non-randomized studies 
demonstrated a reduction in ischemic events when P2Y12 inhibitor therapy was modified if PFT 
indicated HPR (guided therapy) [6, 7]. However, larger randomized controlled trials, using 
different PFT methods and different therapeutic strategies, demonstrated no improved outcome 
with vs. without guided therapy [8-11]. PFT has also been proposed as a means to determine 
when platelet function has recovered sufficiently to enable surgery with minimum bleeding risk 
following P2Y12 inhibitor withdrawal [12] and more recently to guide de-escalation therapy in 
ACS patients treated with PCI [13]. Goals of this position statement are to provide expert 
opinion on the utility of laboratory monitoring of P2Y12 inhibitors to reduce ischemic and bleeding 
events in patients on DAPT and to guide timing of surgery if needed in P2Y12 inhibitor-treated 
patients. 
 
Clopidogrel is a second generation (after ticlopidine) thienopyridine oral antiplatelet drug which 
inhibits ADP-induced platelet aggregation and decreases major adverse cardiovascular events 
(MACE) when combined with aspirin, compared to aspirin alone [1]. Clopidogrel requires 
conversion by cytochrome P450 (CYP) enzymes to an active metabolite (CAM) which 
irreversibly inhibits platelet P2Y12 [14].   
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CYP gene variants influence production of CAM and the pharmacodynamic response to the 
drug [15]. Loss of function alleles leading to reduced generation of CAM (e.g. CYP2C19*2) have 
been associated with poor clinical outcomes [16, 17] leading the Food and Drug Administration 
to issue a boxed warning advising that clopidogrel’s effectiveness may be diminished in 
CYP2C19*2 carriers. Although CYP2C19 variants account for more than 10% of  the variability 
to clopidogrel, other factors may contribute significantly to the variation in clopidogrel 
responsiveness, including non-adherence, underdosing, poor absorption, co-medications 
(atorvastatin, proton pump inhibitors, calcium antagonists), accelerated platelet turnover, 
inflammation and underlying platelet hyperreactivity. Thus, demonstration of HPR, the net effect 
of all of these factors, potentially offers a better predictive marker than these individual factors in 
clopidogrel-treated patients [18].  
 
Newer P2Y12 inhibitors (e.g. prasugrel and ticagrelor) produce greater inhibition of ADP-
dependent platelet function and decrease MACE to a greater extent than clopidogrel [2, 3]. 
Prasugrel, a third generation thienopyridine compound, is, like clopidogrel, a prodrug. However, 
prasugrel’s metabolism to active drug is independent of CYP2C19 and the possibility of 
mutations in this metabolic pathway that could influence platelet inhibition have been previously 
addressed [19]. In contrast to clopidogrel and prasugrel, ticagrelor, a direct P2Y12 antagonist, is 
inherently active and thus is unaffected by CYP polymorphisms [20]. Clopidogrel-treated 
patients with HPR show significantly greater inhibition when switched to prasugrel or ticagrelor 
[21, 22]. Nevertheless, even with these antiplatelet agents on-treatment platelet reactivity is 
variable, albeit less than with clopidogrel [21, 22], thus their clinical benefit may be reduced in 
patients with HPR [5]. Moreover, unfortunately a significant fraction of the studies on the clinical 
efficacy of PFT-guided antiplatelet therapy have been performed by increasing clopidogrel dose 
and not by switching to prasugrel or ticagrelor [6-8, 10]. Thus, there is a need for such studies to 
be undertaken. Arguments against P2Y12 monitoring include cost, variability in individual on-
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treatment platelet responsiveness profile, the availability of P2Y12 inhibitors with reduced 
variability, and the potential use of risk scores [23] to stratify patients. 
 
P2Y12-monitoring can be potentially useful in three situations: 1) to assess risk of thrombosis or 
bleeding in patients treated with P2Y12 inhibitors, 2) to guide antiplatelet therapy, 3) to determine 
the optimum timing of surgery following P2Y12 inhibitor discontinuation.  
There is general consensus that HPR has a negative prognostic value for MACE in P2Y12 
inhibitors-treated patients [5] and, although less certain, a predictive value for bleeding [4, 5]. 
Until 2018, no large randomized clinical trial had demonstrated improved clinical outcomes with 
PFT-guided antiplatelet therapy [8-11]. However, the recent CREATIVE trial [24] showed that 
intensification of antiplatelet therapy (addition of cilostazol) in clopidogrel plus aspirin-treated 
PCI patients with HPR, as measured by thromboelastography, significantly improved clinical 
outcomes (hazard ratio 0.55, 95% CI 0.35-0.87) without increasing bleeding. Thus, despite 
these encouraging results, until this recent finding is replicated, consistent with previous 
guidelines [25], we believe that this strategy cannot be recommended at this time (Table 1). 
Given that the newer P2Y12 inhibitors provide greater platelet inhibition and reduce ischemic 
outcomes compared to clopidogrel, using these agents in patients at high risk for ischemic 
events without P2Y12-monitoring is reasonable and potentially more cost effective than repeated 
testing. However, improved efficacy is associated with enhanced bleeding and limitations exist 
to the use of prasugrel [2, 3]; moreover, HPR is still observed and is associated with increased 
risk of ischemic outcomes [5]. Recently, monitoring prasugrel-treated elderly patients 
undergoing PCI for ACS was not found to be superior to conventional treatment with respect to 
both ischemic and bleeding outcomes [11]. Several explanations have been put forth for the 
failure of large randomized controlled trials to demonstrate improved clinical outcomes with 
PFT-guided antiplatelet therapy. HPR might be a non-modifiable risk factor and/or PFT may not 
affect prognostic factors, such as adherence to treatment, procedure-related technical factors, 
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or coexisting conditions influencing platelet reactivity [10]. Nevertheless, given that platelets 
contribute to arterial thrombosis, greater inhibition of platelet function is predicted to result in 
reduction of MACE. Thus, it has been alternatively proposed [26] that some previous studies 
may have been flawed with respect to one or more of the following: a) study design (e.g. sample 
size, definition of clinical endpoints), b) patient selection (low vs. high risk), c) PFT issues (poor 
predictive value, incorrect cut-off, improper timing), d) inability of alternative therapy to 
overcome HPR. The CREATIVE trial may be an example of an appropriate combination of PFT 
and choice of intensified antiplatelet therapy leading to improved outcomes.[24] Whether 
optimizing additional parameters would result in improved clinical outcomes with P2Y12-
monitoring is unknown, but the results of the CREATIVE trial, registry studies [27] and model-
based analyses [28] suggests this approach deserves additional testing.  
Whether P2Y12-monitoring can be of assistance in deciding on DAPT duration has not been 
assessed. The treatment algorithm for duration of P2Y12 inhibitor therapy suggests that in 
NSTE-ACS or STEMI patients treated with medical therapy or PCI, P2Y12 inhibitor should be 
maintained for up to 12 months, and thereafter it may be reasonable to continue it if risk of 
bleeding is not high [29]. Likewise, in patients with stable ischemic heart disease treated with 
stenting it is reasonable to continue P2Y12 inhibitor beyond 1 or 6 months (for BMS or DES, 
respectively) if risk of bleeding is not high. Long duration ticagrelor 60mg or 90mg twice daily 
significantly reduced ischemic outcomes [30] and virtually eliminated HPR [31]. However, major 
bleeding was also increased in these patients, highlighting the need to consider the balance 
between increased risk of non-fatal bleeding associated with LPR relative to the reduced risk of 
fatal and non-fatal ischaemic events. While studies have shown a connection between risk of 
bleeding and LPR [4, 5], prospective evaluation in clinical trials is required to establish whether 
PFT may guide duration of DAPT. Most recently, a large randomized trial has shown that a 
strategy of early PFT-guided de-escalation to clopidogrel is non-inferior to standard treatment 
with prasugrel in patients with ACS managed with PCI [13], suggesting that PFT may be useful 
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in patients not suitable for prolonged therapy with potent P2Y12 inhibitors.  
Worldwide over three million patients undergo PCI each year, >90% with stenting, and it is 
estimated that ≥5% will need non-cardiac surgery within the first year. Current guidelines state 
that in patients who require non-emergency major non-cardiac surgery, postponing surgery for 
at least 5 days after cessation of ticagrelor or clopidogrel, and 7 days for prasugrel should be 
considered unless the patient is at high risk of ischemic events [32]. Nevertheless, shortening 
the delay to surgery is often highly desirable. PFT demonstrated variation between individuals in 
the time required to recover platelet function following P2Y12 inhibitor discontinuation, and 
prospective studies showed that a strategy based on preoperative PFT reduced post-operative 
bleeding and blood consumption and/or shortened waiting time [33, 34]. These results suggest it 
may be reasonable to decide about surgical timing based on PFT.  
 
Conclusions and recommendations 
Recommendations were based on a multistep consensus process (Figure 1). 
PFT cannot at present be recommended to guide P2Y12 inhibitor choice or select patients most 
likely to benefit of prolonged antiplatelet treatment but may be considered in deciding an early 
de-escalation from prasugrel to clopidogrel in patients considered not suitable for prolonged 
prasugrel therapy (Table 1). 
It is reasonable, in patients requiring surgery, to consider the results of P2Y12 inhibitor 
monitoring to determine the timing of surgery (Table 1). New, larger, prospective studies are 
however warranted to confirm PFT usefulness.  
While present evidence does not support PFT-guided antiplatelet therapy, limitations of the 
studies performed, differences in cost between generic clopidogrel and newer P2Y12 
antagonists, and the enhanced bleeding risk of the latter continue to motivate clinical research 
on this subject. Critical issues in future studies include study design (particularly sample size 
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and control groups), choice of high risk populations, appropriate selection of monitoring test and 
cut off, appropriate timing of (and possibly repeated) testing and switching to alternative therapy 
(i.e. within days rather than weeks of stent placement), and clearly defined clinical efficacy 
outcomes.   
A critical issue remains the most appropriate PFT method: limitations of currently used 
techniques urge further research on new methods. 
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Table 1. Position Statement of the Platelet Physiology Scientific and Standardization 
Committee on the Laboratory Monitoring of P2Y12 Inhibitors  
Recommendation Classa Levelb Refs. 
P2Y12 inhibitor monitoring to assess risk for bleeding or thrombosis during 
prolonged DAPT  
HPR and LPR determined by P2Y12-monitoring as described in 
[4, 5] are associated with risk for ischemic and hemorrhagic 
events (respectively) and therefore may be considered in the 
overall management of patients. Optimal timing and frequency of 
this monitoring is unclear. 
IIa A [4, 5] 
P2Y12 inhibitor monitoring to adjust  P2Y12 inhibitor dose or adjust  P2Y12 
inhibitor selection  
Monitoring P2Y12 inhibition for the purpose of guiding the intensity 
of antiplatelet therapy is not recommended. 
Monitoring P2Y12 inhibition for the purpose of guiding the duration 
of DAPT is not recommended. 
IIb B [8-10, 24] 
P2Y12 inhibitor monitoring for early de-escalation from prasugrel to clopidogrel 
in patients considered not suitable for prolonged prasugrel therapy  
Monitoring P2Y12 inhibition may be considered for early de-
escalation from prasugrel to clopidogrel in patients considered not 
suitable for prolonged prasugrel therapy 
IIb B [13] 
P2Y12 inhibitor monitoring to shorten the time window to surgery following 
P2Y12 inhibitor discontinuation 
 
It is reasonable, in balancing the risk of thrombosis during a delay 
to surgery with the risk of surgical bleeding, to consider the 
results of P2Y12 inhibitor monitoring to determine the timing of 
surgery. 
• A cut-off of TEG MAADP >50 is recommended if this test is 
available. 
• A cut-off of PFA-100®P2Y CT <106 seconds is 
recommended if this test is available. 
 
• For other P2Y12 inhibitor monitoring tests, cut-offs with 
respect to CABG bleeding have not been established. 
However, it may be reasonable to consider proceeding to 
surgery if platelet reactivity is >80% that seen in P2Y12 
inhibitor-free patients. 
IIa B [33, 34] 
IIb C [33, 34] 
aClass of recommendation: IIa, weight of evidence/opinion is in favor of usefulness/efficacy; IIb, usefulness/efficacy is 
less well established by evidence/opinion; III, evidence or general agreement that the given treatment or procedure is 
not useful/effective, and in some cases may be harmful 
bLevel of evidence: A, data derived from multiple randomized clinical trials or meta-analyses; B, data derived from a 
single randomized clinical trial or large non-randomized studies; C, consensus of opinion of the experts and/or small 
studies, retrospective studies, registries.  
Abbreviations: CABG, coronary artery bypass graft; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; 
HPR, high on-treatment platelet reactivity; LPR, low on-treatment platelet reactivity; PFA, platelet function analyzer; 
TEG, thromboelastograph  
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